Post-Surgical Healing Accelerator with Modified Polymer Scaffold

The patent uses composite materials by combining modified natural polymers (keratin, collagen, elastin, fibrin, fibronectin, gelatin, alginate, pectin, cellulose, hyaluronic acid, laminin, or vitronectin) with synthetic substrates. The polymers are chemically modified to include cell-adhesive peptides (such as RGD sequences) that enhance biocompatibility and cell interaction while maintaining structural integrity. This composite approach resolves the contradiction by achieving high biocompatibility through bioactive polymer modifications without requiring overly complex device structures.

The patent applies parameter changes by chemically modifying natural polymers to incorporate cell-adhesive sequences. Specifically, peptides containing RGD (arginine-glycine-aspartic acid) sequences are conjugated to the polymer backbones through controlled chemical reactions. This modification changes the chemical parameters of the polymers to enhance cell interaction and tissue repair efficiency. The manufacturing process remains relatively simple by using established polymer chemistry techniques and standardized peptide conjugation methods, thus resolving the contradiction between improved productivity and manufacturing ease.

The patent applies local quality by creating heterogeneous polymer compositions within the scaffold where different regions contain different ratios or types of modified polymers. For example, the outer layers may contain more structurally stable polymers like collagen or elastin, while inner regions contain more biocompatible and cell-adhesive polymers like fibronectin or laminin. This spatial variation in polymer composition allows the scaffold to simultaneously achieve structural stability where needed and enhanced biocompatibility where cell interaction is most critical, thus resolving the contradiction between these two properties.